Supernus Pharmaceuticals Inc (SUPN)

43.50
NASDAQ : Health Care
Prev Close 43.50
Day Low/High 0.00 / 0.00
52 Wk Low/High 17.25 / 46.45
Avg Volume 652.40K
Exchange NASDAQ
Shares Outstanding 50.70M
Market Cap 2.31B
EPS 1.80
P/E Ratio 22.82
Div & Yield N.A. (N.A)

Latest News

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round

Here's a look at what Jim Cramer had to say about companies of interest to Mad Money viewers.

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Biotech Movers: Anika Up on Strong Analyst Ratings

Biotech Movers: Anika Up on Strong Analyst Ratings

Anika focuses on pain management, tissue regeneration and wound healing.

Short Interest In Supernus Pharmaceuticals Increases 15.4%

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 406,576 share increase in total short interest for Supernus Pharmaceuticals Inc , to 3,053,345, an increase of 15.36% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Supernus Receives Final FDA Approval For Trokendi XR® For Migraine Prophylaxis In Adults And Adolescents

Trokendi XR is the Leading Extended-Release Topiramate Product and Brand of Topiramate

Market Goes on a 'Buy the Dip' Trip

Market Goes on a 'Buy the Dip' Trip

Stocks slowly recovering from early lows.

There's No Rush for the Exits So Far

There's No Rush for the Exits So Far

There's lots of negativity, but dip buyers are showing up.

Shark Bites: Even Without Health Care Vote, Market's Feeling Better

Shark Bites: Even Without Health Care Vote, Market's Feeling Better

Broad strength and good tone mark action.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

Demographic trends that boosted big gains in prior years haven't gone away.

The Bulls Don't Have Enough Juice for 20,000

The Bulls Don't Have Enough Juice for 20,000

But here are 8 stocks that look good to me, right now.

Rev's Forum: Can the Market Find a Second Wind?

Rev's Forum: Can the Market Find a Second Wind?

This is the time of the year when many moves are made for tax reasons.

Big-Cap Tech Names, Biotechs, Oils Lifting Market

Big-Cap Tech Names, Biotechs, Oils Lifting Market

The number of new 12-month highs has climbed to 240.